“Specialty drugs will begin to end as a separate category,” says Bradford L. Kirkman-Liff, DrPH, of Arizona State University’s W. P. Carey School of Business. “More drugs will be excluded by health plans as tiering changes, and all patients — including oncology patients — will have to pay more of their drug costs.”

PHOTOGRAPH BY DAVID SCHMIDT